Cash & Equivalents
Boston Scientific Cash & Equivalents increased by 120.0% to $1.97B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 374.6%, from $414.00M to $1.97B. Over 5 years (FY 2020 to FY 2025), Cash & Equivalents shows an upward trend with a 2.5% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase signals improved liquidity and financial flexibility, while a decrease may indicate heavy capital expenditure, debt repayment, or aggressive share buybacks.
Detailed definition
Represents the most liquid assets on the balance sheet, including physical currency and short-term investments with matu...
Peer comparison
Large-cap technology peers often maintain high cash balances to fund rapid innovation and offset the cyclical nature of consumer electronics.
cash_and_equivalentsHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $296.00M | $410.00M | $1.93B | $299.00M | $240.00M | $242.00M | $928.00M | $400.00M | $409.00M | $382.00M | $865.00M | $384.00M | $793.00M | $803.00M | $414.00M | $345.00M | $388.00M | $893.00M | $1.97B |
| QoQ Change | — | +38.5% | +369.5% | -84.5% | -19.7% | +0.8% | +283.5% | -56.9% | +2.3% | -6.6% | +126.4% | -55.6% | +106.5% | +1.3% | -48.4% | -16.7% | +12.5% | +130.2% | +120.0% |
| YoY Change | — | — | — | — | -18.9% | -41.0% | -51.8% | +33.8% | +70.4% | +57.9% | -6.8% | -4.0% | +93.9% | +110.2% | -52.1% | -10.2% | -51.1% | +11.2% | +374.6% |
Cash & Equivalents at Other Companies
Frequently Asked Questions
- What is Boston Scientific's cash & equivalents?
- Boston Scientific (BSX) reported cash & equivalents of $1.97B in Q4 2025.
- How has Boston Scientific's cash & equivalents changed year-over-year?
- Boston Scientific's cash & equivalents increased by 374.6% year-over-year, from $414.00M to $1.97B.
- What is the long-term trend for Boston Scientific's cash & equivalents?
- Over 5 years (2020 to 2025), Boston Scientific's cash & equivalents has grown at a 2.5% compound annual growth rate (CAGR), from $1.73B to $1.97B.
- What does cash & equivalents mean?
- Money in the bank and very short-term investments that can be turned into cash almost instantly.